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Summary
Background Data on causes of vision impairment and blindness are important for development of public health 
policies, but comprehensive analysis of change in prevalence over time is lacking.
Methods We did a systematic analysis of published and unpublished data on the causes of blindness (visual acuity in 
the better eye less than 3/60) and moderate and severe vision impairment ([MSVI] visual acuity in the better eye less 
than 6/18 but at least 3/60) from 1980 to 2012. We estimated the proportions of overall vision impairment attributable 
to cataract, glaucoma, macular degeneration, diabetic retinopathy, trachoma, and uncorrected refractive error in 
1990–2010 by age, geographical region, and year.
Findings In 2010, 65% (95% uncertainty interval [UI] 61–68) of 32·4 million blind people and 76% (73–79) of 
191 million people with MSVI worldwide had a preventable or treatable cause, compared with 68% (95% UI 65–70) of 
31·8 million and 80% (78–83) of 172 million in 1990. Leading causes worldwide in 1990 and 2010 for blindness were 
cataract (39% and 33%, respectively), uncorrected refractive error (20% and 21%), and macular degeneration (5% and 
7%), and for MSVI were uncorrected refractive error (51% and 53%), cataract (26% and 18%), and macular 
degeneration (2% and 3%). Causes of blindness varied substantially by region. Worldwide and in all regions more 
women than men were blind or had MSVI due to cataract and macular degeneration.
Interpretation The diﬀ erences and temporal changes we found in causes of blindness and MSVI have implications 
for planning and resource allocation in eye care.
Funding Bill & Melinda Gates Foundation, Fight for Sight, Fred Hollows Foundation, and Brien Holden Vision Institute.
Introduction
Data on the causes of vision impairment and blindness 
form an important basis for recommendations in public 
health policies, such as planning of national budgets and 
health services, and are important for scientiﬁ c research. 
Population-based studies done in the past 20 years have 
revealed that cataract, glaucoma, macular degeneration, 
diabetic retinopathy, trachoma, and uncorrected 
refractive error are the most common causes of blindness 
and vision impairment worldwide.1–4 Most studies have 
focused on one population within a circumscribed region 
and frequently within one ethnic group. Important 
diﬀ erences between ethnic groups, regions of habitation, 
demographic parameters, lifestyle, exposure to 
environmental factors, and other factors, however, can 
aﬀ ect the causes and prevalence of vision loss. The 
information about vision loss, therefore, might not be 
relevant at the worldwide level. Assessment of causes of 
vision impairment, their trends, and the eﬀ ects of 
interventions is most accurate when repeated surveys are 
done within the same population, but such data are 
rarely collected. In their absence, estimates of patterns 
and trends in vision impairment derived from available 
data might be useful to set policy priorities.
Estimates of the leading causes of vision impairment 
worldwide have been generated by meta-analyses.5–8 The 
ﬁ rst of these, done by Thylefors and colleagues in 1995,5 
estimated that 38 million people were blind, mainly due 
to cataract, trachoma, and glaucoma. A lack of prevalence 
data for diabetic retinopathy and macular degeneration 
precluded an estimate of their burden at that time. The 
Global Burden of Disease, Risk Factors and Injury Study 
2010 (GBD), which started in 2007, aimed to calculate 
comparable estimates of burden of disease, injuries, and 
risk factors from 1990 and 2010.9,10 The Vision Loss Expert 
Group (VLEG) of the GBD published its methods for a 
systematic review of published and unpublished data 
from population-based studies that reported the 
prevalence of blindness and vision impairment in 
1980–2012.11 We have found an decrease in age-
standardised prevalence of blindness and MSVI over the 
past 20 years. Nevertheless, because of population growth 
and the increase in the number of elderly adults, the 
blind population has remained stable and the vision-
impaired population might have increased.12 
Here we report a systematic analysis of the VLEG GBD 
dataset. We aimed to estimate the main causes of blindness 
and vision impairment worldwide and by geographical 
region, including analysis of trends over time.
Methods
Study design
We estimated trends in causes of vision impairment, 
including analysis of uncertainties, by age, sex, and 
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geographical region (we used the 21 regions deﬁ ned in 
the GBD; appendix pp 1–2). We estimated what 
proportions of overall vision impairment were from six 
common causes of blindness and vision impairment: 
cataract, glaucoma, macular degeneration, diabetic 
retinopathy, trachoma, and uncorrected refractive error 
(table 1). We also estimated the proportions of blindness 
and vision impairment related to other causes. We 
calculated the causes of moderate and severe vision 
impairment (MSVI), deﬁ ned as visual acuity in the better 
eye lower than 6/18 but at least 3/60 at presentation, and 
blindness, deﬁ ned as visual acuity in the better eye lower 
than 3/60 at presentation. We did our analysis in three 
steps: data identiﬁ cation and access, as described 
previously;11 estimation of fractions for each cause, by 
severity of vision impairment, sex, age, and region, as 
described in this report; and application of cause 
fractions to the prevalence of all-cause presenting vision 
impairment, which was estimated previously.12
Data sources
The methods for the data search have been published 
previously.11 Brieﬂ y, we searched for articles published 
from Jan 1, 1980, to Jan 31, 2012 (panel). Our initial 
search identiﬁ ed 14 908 relevant manuscripts, which 
were distilled by application of rigorous selection criteria 
and review by an expert panel to 243 high-quality, 
population-based studies (appendix pp 3–18). Data from 
epidemiological studies that reported prevalence 
disaggregated by cause (128 studies) were used to 
calculate the proportions of blindness and MSVI that 
were due to cataract, glaucoma, macular degeneration, 
diabetic retinopathy, trachoma, and undercorrection of 
refractive error or other causes. Many countries with 
endemic trachoma lack epidemiological data on 
trachomatous blindness and, therefore, we also obtained 
data from the authors of an unpublished working paper, 
which uses trichiasis data extracted from the Global Atlas 
of Trachoma13 to model the prevalence of trachoma-
related vision impairment in speciﬁ c countries 
(Smith JL, Solomon A, Haddad D, Brooker S, personal 
communication). 
Statistical analysis
We used the DisMod-MR model from GBD to calculate 
the fraction of vision impairment due to cataract, 
glaucoma, macular degeneration, and diabetic retinopathy. 
This model is a Bayesian multi-level regression tool that 
incorporates age.10,14 Brieﬂ y, DisMod-MR includes the 
following elements: covariates that predict variation in the 
true proportion of vision impairment from each disease 
(eg, year); ﬁ xed eﬀ ects that adjust for diﬀ erences in 
deﬁ nitions (eg, whether causes were reported on the basis 
of vision at presentation vs best-corrected vision); a 
hierarchical model structure that ﬁ ts random intercepts in 
individual countries derived from the data observed in a 
country, its region, and in other regions, on the basis of 
the availability and consistency of country-speciﬁ c and 
region-speciﬁ c data; a piecewise linear spline model of the 
age pattern; and a ﬁ xed eﬀ ect for data on men and boys. 
We used a speciﬁ c set of parameters for each cause of 
vision impairment (appendix p 19). We assessed all model 
ﬁ ts visually.
For causes of cataract we ﬁ tted two DisMod-MR 
models, one with data on the proportion of blindness 
caused by cataract and one for MSVI caused by cataract 
(appendix p 19). We ﬁ tted each model with three 
covariates: an indicator variable that described whether 
the data were based on visual acuity at presentation or 
best-corrected visual acuity, a year covariate that allowed 
for analysis of time trends, and a country covariate that 
Description
Cataract Age-related cataract leading to progressive visual impairment
Glaucoma All types of glaucoma combined
Macular degeneration Degeneration of macula and posterior pole, including age-related macular 
degeneration, myopic maculopathy, macular hole, and any other macular disorder
Diabetic retinopathy Diabetic retinopathy and sequelae
Trachoma Trachoma-related corneal scarring
Uncorrected refractive 
error
Estimated as the diﬀ erence between vision impairment at presentation and 
best-corrected sight (includes aphakia)
Other All other causes, including unidentiﬁ ed causes
Table 1: Deﬁ nitions of causes of blindness and vision impairment used in this study
Panel: Research in context
Systematic review
We did a systematic review of articles published from January, 1980, to January, 2012, in 
the following sources: Medline, Embase, and the WHO library information system. Search 
terms included concepts to describe “blindness”, “VI”, “population”, “eye”, “survey”, and a 
list of disorders that aﬀ ect the eyes. We identiﬁ ed additional unpublished data sources 
through personal communication with researchers identiﬁ ed in the literature search.11 
Literature reviews published by WHO and the WHO Prevention of Blindness and Deafness 
programme have been used to make worldwide estimates of numbers of people blind or 
with vision impairment. The latest of studies included literature published in 2000–10, 
and the analysis was limited to three age groups, with no breakdown by sex, provision of 
a point estimate for 2010, or estimates for the six WHO epidemiological subregions 
within a more limited timeframe.8
Interpretation
We have previously reported prevalence of vision impairment and blindness worldwide and 
shown that the age-standardised prevalence of both has decreased between 1990 and 
2010.12 This study added to those ﬁ ndings by investigating the contribution of various causes 
to the burden of vision loss, and by analysing temporal trends in contribution. The 
proportions of vision impairment and blindness due to cataract and trachoma decreased over 
the study period of 20 years; those due to glaucoma, macular degeneration, diabetic 
retinopathy, and uncorrected refractive error increased. By contrast with the WHO data, we 
undertook a granular analysis, and present data in 5-year age groups and by sex, provide 
time-series estimates for the period 1990–2010, and break them down geographically for 
21 regions. Thus, our estimates of prevalence are more detailed and show temporal change. 
This analysis, therefore, provides useful information for the setting of priorities, development 
of policies, and planning. Additionally, the data might provide a resource for advocacy eﬀ orts 
to help mobilise resources for eye-care services from governments, donors, and civil society.
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reﬂ ected access to health systems.15 We have shown 
previously that the latter variable, which was developed 
for the GBD, can predict the prevalence of all-cause 
vision impairment.12 We predicted the proportion of best-
corrected vision impairment that was caused by cataract.
We ﬁ tted one DisMod-MR model for each of glaucoma, 
macular degeneration, and diabetic retinopathy 
(appendix p 19). In the models for glaucoma and macular 
degeneration we used three covariates: an indicator 
variable that described whether the data were for 
blindness or for MSVI, another that described whether 
the data were based on visual acuity at presentation or 
best-corrected visual acuity, and a country covariate that 
reﬂ ected access to health systems. We made two sets of 
predictions for glaucoma and macular degeneration, one 
for best-corrected blindness and one for best-corrected 
MSVI. For diabetic retinopathy, we used three covariates: 
an indicator variable that described whether the data 
were based on visual acuity at presentation or best-
corrected visual acuity, a year covariate to allow for time 
trends, and a country covariate that reﬂ ected access to 
health systems. We predicted the proportion best-
corrected visual acuity caused by diabetic retinopathy, 
and used the same proportions for blindness and MSVI.
Estimates for the prevalence of trachoma were derived 
from nationally representative surveys of vision 
impairment and from a Bayesian predictive model that 
used data on the prevalence of trichiasis, a clinical stage 
of trachoma that is a direct cause of visual impairment, 
as described above. In 16 countries we obtained data on 
the proportion of vision impairment caused by trachoma 
from national surveys, in 25 countries we based 
estimates on trichiasis prevalence, and in two countries 
we used both sources of data. On the basis of national 
survey data, we made estimates for ﬁ ve countries that 
WHO does not currently classify as having endemic 
disease: Dominican Republic, Ecuador, Paraguay, Saudi 
Arabia, and Thailand.16 For another 20 countries that are 
deemed by WHO to be endemic for trachoma16 we could 
obtain no data and conservatively assigned each as 
having no trachoma-related vision impairment. These 
countries were predominantly small countries that 
would not aﬀ ect regional or worldwide estimates (eg, the 
Solomon Islands) or those that had no data because the 
prevalence of trachomatous blindness is low (eg, 
Pakistan). For all countries classiﬁ ed as not having 
endemic trachoma, we estimated no trachoma-related 
vision impairment.
With these data, we ﬁ tted the following regression 
(equation, appendix p 19):
logit(PT) = β0 + β1sex + β2year + β3vision level + β4country
Vision level was an indicator variable used to indicate 
whether data related to blindness or MSVI. Country was 
a ﬁ xed eﬀ ect, sex was an indicator variable, and year was 
a linear covariate. We used the ﬁ tted coeﬃ  cients from 
this regression model to predict the proportion of 
blindness and MSVI caused by trachoma in men and 
women in each endemic country, for 1990 and 2010.
As described previously,12 the total prevalence of vision 
impairment and its uncertainty were estimated from 
data on presenting visual acuity and best-corrected 
visual acuity. This model implicitly estimated the 
diﬀ erence between the prevalence of blindness (and of 
MSVI) on the basis of visual acuity and on best-corrected 
visual acuity. We interpreted this diﬀ erence as the 
prevalence of vision impairment caused by uncorrected 
refractive error.
The proportions of best-corrected vision attributable to 
causes other than cataract, macular degeneration, 
glaucoma, or trachoma were calculated with data from 
surveys that included at least cataract and macular 
degeneration (only 3% of survey data did not report 
glaucoma). We modelled these data with DisMod-MR 
(appendix p 19). The covariates were year and an indicator 
variable for MSVI. We made two sets of predictions, one 
for blindness and one for MSVI. We deducted the 
estimated proportions of blindness and MSVI caused by 
diabetic retinopathy to ﬁ nd the proportion of best-
corrected vision caused by other vision impairment. This 
category comprises avoidable, unavoidable, and 
unidentiﬁ ed causes.
DisMod-MR produced 1000 draws for each country, 
sex, age, and year  (1990 and 2010). We used the mean of 
the draws as the central estimate. For computational 
eﬃ  ciency, we selected every second draw (total 500) to 
propagate uncertainty. We also extracted the central 
estimate and 500 draws for uncorrected refractive error.12 
For the central estimate and each draw, we normalised 
the proportions attributable to all causes of best-corrected 
vision loss (cataracts, glaucoma, macular degeneration, 
diabetic retinopathy, trachoma, and other) to sum to the 
remaining vision impairment not due to refractive error. 
We applied the results to previously estimated prevalence 
of blindness and MSVI by country, age, sex, and draw.12 
We calculated uncertainty intervals (UIs) as the 
2·5th–97·5th percentiles of the distribution of draws.
For presentation, we age-standardised prevalence with 
the WHO reference population.17 We also calculated 
numbers of people with blindness and MSVI by cause 
in each region to reﬂ ect that region’s population size 
and age distribution.
Role of the funding sources
The sponsors had no involvement in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit the paper for publication.
Results
At least two studies were identiﬁ ed for 18 of 21 GBD 
study regions. No studies with cause-speciﬁ c data were 
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identiﬁ ed for central Africa or eastern Europe and one 
study was identiﬁ ed for central Europe. No studies were 
identiﬁ ed for 126 (66%) of 191 countries.
In 1990 and in 2010, the leading causes of blindness 
worldwide, based on presenting visual acuity 
measurements, were cataract, uncorrected refractive 
Cataract Uncorrected 
refractive error
Macular 
degeneration
Glaucoma Diabetic 
retinopathy
Trachoma Other causes/ 
unidentiﬁ ed
1990
Asia Paciﬁ c, high income 18·8% (13·3–25·6) 14·0% (8·4–18·2) 14·9% (10·3–21·3) 9·0% (6·0–12·8) 4·8% (3·3–7·2) 0 38·5% (30·4–46·4)
Asia, central 29·0% (24·3–33·6) 13·7% (8·2–17·6) 11·6% (8·8–15·3) 9·5% (7·3–12·6) 3·4% (2·7–4·6) 0 33·0% (28·7–37·5)
Asia, east 37·2% (29·7–45·4) 13·5% (8·0–17·5) 5·0% (3·2–7·9) 3·9% (2·6–5·8) 1·0% (0·65–1·6) 5·4% (4·4–6·6) 34·1% (26·5–42·6)
Asia, south 47·7% (39·5–59·4) 35·4% (20·3–45·9) 1·4% (1·0–1·9) 2·4% (1·7–3·3) 1·9% (1·3–2·9) 0·25% (0·20–0·35) 10·9% (8·6–13·9)
Asia, southeast 47·2% (42·0–51·7) 13·0% (7·8–17·1) 3·7% (2·9–5·0) 3·3% (2·6–4·4) 1·1% (0·88–1·4) 0·33% (0·25–0·45) 31·4% (27·2–36·1)
Australasia 19·7% (15·2–26·0) 14·0% (8·4–18·0) 16·8% (12·9–22·2) 9·6% (7·4–13·1) 4·5% (3·4–6·2) 0 35·5% (29·2–41·6)
Caribbean 32·9% (28·3–38·0) 13·3% (8·0–17·4) 4·5% (3·4–6·0) 9·1% (7·3–11·8) 2·1% (1·7–2·8) 0·03% (0·02–0·04) 38·0% (33·4–42·7)
Europe, central 26·9% (23·1–31·5) 13·8% (8·2–17·9) 12·2% (9·3–15·6) 10·2% (7·9–13·3) 3·5% (2·8–4·5) 0 33·4% (28·6–38·3)
Europe, eastern 25·3% (18·7–32·5) 13·8% (8·3–17·7) 13·1% (9·1–19·2) 10·8% (7·7–15·4) 3·5% (2·4–5·4) 0 33·7% (25·5–42·0)
Europe, western 19·2% (16·2–22·7) 13·9% (8·3–18·0) 16·1% (13·4–19·6) 9·0% (7·4–11·3) 4·4% (3·8–5·6) 0 37·4% (32·4–43·0)
Latin America, Andean 37·5% (30·5–44·2) 13·3% (8·0–17·4) 3·7% (2·6–5·5) 6·8% (5·0–9·6) 2·1% (1·5–3·1) 0 36·6% (30·4–43·0)
Latin America, central 32·9% (27·6–38·6) 13·2% (8·0–17·2) 4·6% (3·5–6·2) 8·6% (6·7–11·7) 2·2% (1·7–2·9) 0 38·6% (32·6–43·8)
Latin America, southern 24·3% (18·5–31·2) 13·6% (8·1–17·6) 14·6% (10·6–19·6) 9·3% (6·6–12·6) 5·4% (3·9–8·0) 0 32·9% (25·0–40·1)
Latin America, tropical 32·7% (23·9–42·5) 13·4% (8·0–17·3) 5·0% (3·1–8·0) 9·2% (5·9–14·0) 2·5% (1·6–4·1) 0 37·2% (29·0–46·1)
North Africa/Middle East 29·2% (25·5–33·4) 12·7% (7·6–16·6) 6·4% (5·2–8·0) 5·6% (4·4–7·6) 2·7% (2·3–3·5) 5·1% (3·4–6·2) 38·3% (34·2–42·8)
North America, high income 17·4% (12·5–22·8) 14·0% (8·4–18·1) 16·4% (12·2–21·4) 9·2% (6·7–11·9) 4·1% (3·0–5·8) 0 39·0% (32·0–46·9)
Oceania 43·3% (35·2–49·9) 13·4% (8·0–17·5) 3·3% (2·3–4·7) 2·8% (2·0–4·1) 1·2% (0·85–1·8) 0 36·0% (29·7–43·7)
Sub-Saharan Africa, central 41·0% (33·3–47·5) 13·3% (7·8–17·2) 4·8% (3·5–7·1) 3·3% (2·4–4·6) 2·5% (1·8–3·6) 0·94% (0·52–1·6) 34·2% (28·4–41·2)
Sub-Saharan Africa, east 35·4% (31·7–39·8) 12·9% (7·7–17·1) 4·1% (3·4–5·1) 2·9% (2·4–3·6) 2·0% (1·6–2·5) 13·5% (11·7–15·1) 29·2% (26·4–32·5)
Sub-Saharan Africa, southern 34·0% (29·0–39·8) 13·2% (7·8–17·3) 6·9% (5·5–8·9) 5·4% (4·2–7·3) 2·9% (2·0–4·1) 1·6% (1·1–2·6) 36·1% (30·1–42·4)
Sub-Saharan Africa, west 37·1% (32·1–41·9) 12·9% (7·6–17·0) 4·1% (3·4–5·4) 2·9% (2·4–3·8) 2·4% (1·9–3·1) 7·3% (6·6–8·6) 33·4% (28·9–38·4)
Worldwide 38·6% (35·2–42·0) 19·9% (14·9–24·9) 4·9% (4·4–5·8) 4·4% (4·0–5·1) 2·1% (1·9–2·5) 2·8% (2·3–3·1) 27·4% (24·9–30·0)
2010
Asia Paciﬁ c, high income 13·1% (8·3–20·8) 14·1% (8·4–18·2) 19·5% (12·3–28·8) 11·7% (7·1–18·8) 4·3% (2·6–7·1) 0 37·3% (25·9–46·7)
Asia, central 24·2% (18·6–29·7) 13·9% (8·3–18·0) 13·3% (9·4–18·1) 12·0% (8·7–17·2) 4·0% (2·9–6·0) 0 32·6% (26·4–38·9)
Asia, east 28·2% (19·3–37·3) 13·8% (8·2–17·8) 6·9% (4·5–11·0) 5·4% (3·5–8·5) 1·1% (0·61–2·0) 2·0% (1·6–2·5) 42·7% (33·4–51·3)
Asia, south 41·7% (33·0–51·6) 36·0% (20·7–46·6) 2·6% (1·7–4·2) 4·7% (3·3–7·5) 2·8% (1·7–4·8) 0·15% (0·11–0·24) 12·1% (9·1–17·3)
Asia, southeast 42·0% (34·8–47·9) 13·4% (8·0–17·4) 5·9% (4·7–8·3) 5·6% (4·3–8·2) 1·4% (1·1–2·1) 0·15% (0·11–0·23) 31·5% (25·8–37·3)
Australasia 14·5% (8·5–22·4) 14·1% (8·4–18·1) 17·7% (11·1–26·3) 11·3% (6·8–18·8) 4·3% (2·5–7·7) 0 38·2% (25·9–48·1)
Caribbean 30·2% (23·8–37·1) 13·5% (8·1–17·8) 6·1% (4·3–8·9) 11·2% (8·0–15·1) 2·3% (1·7–3·4) 0·01% (0·01–0·02) 36·8% (30·7–42·7)
Europe, central 21·6% (17·0–26·7) 14·0% (8·3–18·0) 15·4% (10·9–20·8) 12·5% (9·1–17·0) 3·7% (2·8–5·5) 0 32·9% (26·7–38·3)
Europe, eastern 20·6% (13·1–30·5) 14·0% (8·4–18·0) 16·6% (10·1–25·1) 13·5% (8·6–20·6) 4·0% (2·5–6·9) 0 31·3% (21·0–40·9)
Europe, western 13·8% (11·2–17·9) 14·0% (8·4–18·1) 16·1% (12·5–20·1) 10·6% (8·2–14·0) 4·2% (3·4–5·9) 0 41·4% (35·4–46·5)
Latin America, Andean 31·0% (23·3–38·7) 13·6% (8·2–17·7) 6·2% (4·1–9·2) 11·7% (7·9–17·1) 2·5% (1·6–4·2) 0 35·1% (26·7–43·0)
Latin America, central 26·4% (20·9–32·3) 13·5% (8·1–17·5) 6·8% (4·9–9·9) 13·0% (9·6–18·2) 2·5% (1·9–3·7) 0 37·8% (30·4–44·6)
Latin America, southern 18·0% (12·0–25·8) 13·7% (8·2–17·7) 19·5% (13·2–26·8) 12·6% (7·9–19·3) 5·5% (3·6–9·1) 0 30·8% (21·8–39·3)
Latin America, tropical 23·9% (16·2–32·5) 13·6% (8·1–17·5) 9·1% (5·7–13·3) 15·5% (9·6–21·9) 2·9% (1·9–4·6) 0 35·1% (26·3–43·7)
North Africa/Middle East 23·4% (18·7–28·6) 13·1% (7·8–17·1) 10·3% (7·8–13·6) 9·6% (7·5–13·2) 3·5% (2·8–5·0) 2·6% (1·6–3·3) 37·6% (31·6–43·3)
North America, high income 12·7% (8·3–18·7) 14·1% (8·4–18·2) 16·4% (10·8–23·4) 10·7% (7·0–15·7) 3·9% (2·7–6·4) 0 42·2% (32·6–50·1)
Oceania 40·6% (31·5–48·6) 13·6% (8·1–17·7) 4·6% (3·1–7·6) 4·2% (2·5–7·2) 1·4% (0·91–2·4) 0 35·6% (27·4–45·0)
Sub-Saharan Africa, central 34·8% (25·3–42·5) 13·6% (8·0–17·5) 6·9% (4·7–11·0) 5·2% (3·4–8·8) 3·0% (2·0–5·2) 0·44% (0·24–0·82) 36·0% (28·4–44·0)
Sub-Saharan Africa, east 36·7% (31·9–41·5) 13·1% (7·8–17·2) 5·8% (4·6–7·7) 4·0% (3·1–5·4) 2·4% (1·9–3·4) 8·1% (6·8–9·5) 29·9% (25·6–34·5)
Sub-Saharan Africa, southern 31·2% (24·6–39·0) 13·5% (8·0–17·7) 9·7% (6·7–14·1) 7·3% (5·2–10·4) 3·4% (2·1–5·8) 0·69% (0·45–1·1) 34·0% (27·1–42·2)
Sub-Saharan Africa, west 33·8% (28·1–39·3) 13·2% (7·8–17·3) 6·2% (4·8–8·4) 4·4% (3·4–5·9) 3·1% (2·4–4·9) 3·6% (3·2–4·6) 35·6% (30·1–41·6)
Worldwide 33·4% (29·6–36·4) 20·9% (15·2–25·9) 6·6% (6·0–7·9) 6·6% (5·9–7·9) 2·6% (2·2–3·4) 1·4% (1·2–1·7) 28·6% (26·1–31·5)
Data are proportions (95% uncertainty intervals).
Table 2: Causes of blindness in 21 regions and worldwide in 1990 and 2010
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Figure 1: Prevalence of blindness in adults aged 50 years and older, by cause, in 21 regions and worldwide, from 1990 to 2010
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error, and macular degeneration (table 2, ﬁ gure 1). 
Avoidable vision loss due to preventable or treatable 
causes can be deﬁ ned as vision loss due to cataract, 
uncorrected refractive error, trachoma, glaucoma, and 
diabetic retinopathy. Avoidable vision loss due to 
preventable or treatable causes aﬀ ected 68% (95% UI 
65–70) of 31·8 million blind people in 1990, but by 2010, 
the proportion had decreased signiﬁ cantly to 65% (61–68) 
of 32·4 million blind. Additionally, the rate of preventable 
or treatable MSVI decreased from 1990 (80%, 78–83) to 
2010 (76%, 73–79).
Breakdown of the worldwide averages showed large 
diﬀ erences in the causes of blindness between regions 
(ﬁ gure 1). In 2010, the proportion of blindness caused by 
cataracts ranged from less than 15%, with the lowest 
values seen in high-income regions, to more than 40% in 
south and southeast Asia and Oceania. The proportion of 
blindness caused by macular degeneration was higher in 
regions with older populations, such as high-income 
regions and southern Latin America, and central and 
eastern Europe, where more than 15% of blindness was 
caused by macular degeneration, whereas the proportion 
was much lower in regions such as south Asia (2·6%, 
95% UI 1·7–4·2; table 2). The proportion of blindness 
caused by glaucoma varied notably, with the lowest 
values being seen in south Asia (4·7%, 3·3–7·5), east and 
west sub-Saharan Africa (4·0%, 3·1–5·4 and 4·4%, 
3·4–5·9, respectively), and Oceania (4·2%, 2·5–7·2), and 
the highest value being seen in tropical Latin America 
(15·5%, 9·6–21·9). We estimated that there was no 
trachoma-related blindness in 13 of 21 world regions, but 
that 3·6% (3·2–4·6) of blindness in west sub-Saharan 
Africa and 8·1% (6·8–9·5) in east sub-Saharan Africa 
was caused by trachoma-related corneal scars in 2010.
Worldwide, the leading causes of MSVI were 
uncorrected refractive error, cataract, and macular 
degeneration (table 3, ﬁ gure 2). In 2010, uncorrected 
refractive error caused a larger proportion of MSVI in 
south Asia (65·4%, 95% UI 62·0–72·0) than in other 
regions (range 43·2–48·1%). As with blindness, the 
proportion of MSVI caused by cataract was smallest in 
the highest-income regions (range 13·0–13·8%) and 
largest in south Asia (21·4%, 95% UI 16·1–24·2) and 
southeast Asia (22·7%, 17·9–27·4). The proportion of 
MSVI caused by macular degeneration was small in 
comparison (range 1·0–8·0%). Glaucoma, diabetic 
retinopathy, and trachoma caused less than 5·5% of 
MSVI in all regions.
In all regions and worldwide, higher proportions of 
blindness and MSVI were caused by cataract and macular 
degeneration in women than in men. Worldwide, 
cataract caused 35·5% (95% UI 31·0–39·1) of blindness 
in women, compared with 30·1% (25·2–33·7) in men, 
and for MSVI the values were 20·2% (17·2–23·0) and 
15·9% (12·8–18·6), respectively. Likewise, macular 
degeneration caused 7·3% (6·4–8·9) of blindness in 
women worldwide, compared with 5·5% (4·8–6·8) in 
men. The disparities between sexes were less for all other 
causes of vision impairment.
The age-standardised prevalence of trachoma, cataract, 
and uncorrected refractive error worldwide between 1990 
and 2010 showed the greatest declines (appendix 
pp 20–23). For glaucoma, macular degeneration, and 
diabetic retinopathy, prevalence had declined less (for 
blindness) or increased slightly (for MSVI).
The number of people aﬀ ected by blindness due 
to cataract decreased between 1990 and 2010 from 
12·3 million (95% UI 10·7 million to 14·2 million) to 
10·8 million (9·3 million to 12·3 million), and for MSVI 
fell from 44·0 million (35·6 million to 52·4 million) to 
35·2 million (29·6 million to 43·5 million; appendix 
pp 20–23). In 2010, the age-standardised prevalence of 
blindness and MSVI caused by cataract in people aged 
50 years or older was 0·7% (95% UI 0·6–0·8) and 2·2% 
(1·9–2·7), respectively. These values represent declines 
from 1990 (1·3%, 1·1–1·5 for blindness and 4·4%, 3·6–5·2 
for MSVI; appendix pp 20–23). The decline in blindness or 
MVSI due to cataract was greatest in east Asia, tropical 
Latin America, and western Europe, in all of which 
prevalence fell by more than half. The region with the least 
decline was east sub-Saharan Africa (appendix pp 24–27).
The number of people with blindness or MSVI caused 
by trachoma decreased from 0·87 million (95% CI 
0·70 million to 1·0 million) and 2·2 million (1·5 million 
to 2·8 million) in 1990 to 0·45 million (0·38 million to 
0·54 million) and 1·4 million (1·1 million to 1·8 million) 
in 2010, respectively. The age-standardised prevalence of 
trachoma as a cause of blindness and MSVI combined 
was 0·29% (0·22–0·34) in 1990 and 0·11% (0·09–0·13) 
in 2010. The proportion of global blindness caused by 
trachoma decreased from 2·8% in 1990 (2·3–3·1) to 
1·4% (1·2–1·7) in 2010; for MSVI the values are 1·3% 
(1·0–1·5) and 0·7% (0·6–0·9), respectively. The greatest 
decreases were seen in east and west sub-Saharan Africa 
(appendix pp 24–27).
The number of people worldwide aﬀ ected by blindness 
or MSVI caused by uncorrected refractive error increased 
from 6·3 million (4·4 million to 8·1 million) and 
88·0 million (69·9 million to 103·3 million) in 1990 to 
6·8 million (4·7 million to 8·8 million) and 101·2 million 
(87·88 million to 125·5 million) in 2010, respectively. The 
age-standardised prevalence of uncorrected refractive 
error as a cause for adult blindness and MSVI combined, 
however, was 7·5% (6·1–8·5%) in 1990 and 5·7% 
(5·0–6·9%) in 2010. Between 1990 and 2010, the 
percentage reductions in age-standardised prevalence of 
uncorrected refractive error as a cause for adult blindness 
and MSVI combined were greatest in tropical Latin 
America (36%), central Asia (36%), and high-income 
Asia Paciﬁ c (35%), and smallest in eastern sub-Saharan 
Africa (17%), Oceania (20%), and western sub-Saharan 
Africa (21%).
The worldwide age-standardised prevalence for 
blindness and for MSVI declined substantially from 1990 
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to 2010. Of this overall decline in vision impairment, 
around half was a result of decline in vision impairment 
caused by cataracts. A further 20% and 45% of the 
reductions in the prevalence of blindness and MSVI, 
respectively, resulted from declines in uncorrected 
refractive error. Despite the large decline in the 
Cataract Uncorrected 
refractive error
Macular 
degeneration
Glaucoma Diabetic 
retinopathy
Trachoma Other causes/ 
unidentiﬁ ed
1990
Asia Paciﬁ c, high income 22·8% (18·1–29·4) 47·9% (38·4–54·1) 3·5% (2·4–5·1) 2·3% (1·5–3·5) 2·8% (1·9–4·1) 0 20·8% (15·8–27·3)
Asia, central 26·6% (22·1–31·2) 45·1% (36·8–51·6) 3·3% (2·4–4·6) 2·3% (1·8–3·3) 2·0% (1·6–3·0) 0 20·6% (17·3–25·1)
Asia, east 24·1% (18·9–29·4) 44·8% (36·4–51·7) 3·1% (1·9–5·2) 0·92% (0·57–1·5) 0·68% (0·43–1·1) 2·9% (2·3–3·8) 23·6% (17·8–29·3)
Asia, south 26·7% (21·4–29·5) 63·9% (60·0–70·8) 0·45% (0·32–0·61) 0·66% (0·47–0·90) 1·2% (0·76–1·8) 0·13% (0·10–0·17) 7·0% (5·4–8·6)
Asia, southeast 30·1% (25·4–35·2) 42·8% (34·2–49·7) 0·93% (0·72–1·3) 0·83% (0·65–1·1) 0·76% (0·59–1·0) 0·20% (0·15–0·28) 24·4% (20·4–29·4)
Australasia 21·9% (17·2–27·6) 46·5% (37·4–53·1) 6·6% (4·6–9·5) 2·4% (1·7–3·4) 2·6% (1·9–3·6) 0 20·1% (15·8–25·7)
Caribbean 22·8% (18·4–27·4) 43·4% (35·6–50·4) 0·74% (0·57–1·0) 3·0% (2·2–4·1) 1·5% (1·2–2·1) 0·02% (0·01–0·03) 28·6% (23·8–34·0)
Europe, central 26·6% (21·9–31·7) 45·2% (36·1–52·1) 4·7% (3·4–6·5) 2·5% (1·9–3·3) 2·0% (1·5–2·7) 0 19·1% (15·8–23·4)
Europe, eastern 26·4% (20·4–32·1) 44·8% (36·6–51·3) 4·3% (2·7–6·9) 2·7% (1·8–4·2) 2·0% (1·4–3·2) 0 19·8% (14·8–26·0)
Europe, western 24·1% (19·9–28·8) 46·6% (37·9–53·0) 4·1% (3·3–5·2) 2·3% (1·8–3·0) 2·5% (2·0–3·3) 0 20·5% (17·2–24·5)
Latin America, Andean 22·9% (17·8–28·6) 43·4% (35·0–50·8) 1·4% (0·99–2·2) 2·1% (1·4–3·0) 1·6% (1·1–2·4) 0 28·7% (23·4–34·8)
Latin America, central 21·6% (17·3–26·0) 43·9% (35·6–50·8) 1·7% (1·2–2·5) 2·5% (1·9–3·7) 1·6% (1·2–2·2) 0 28·7% (24·0–34·4)
Latin America, southern 26·5% (21·1–32·6) 44·4% (35·6–51·5) 4·2% (2·9–6·2) 2·4% (1·7–3·7) 3·1% (2·3–5·0) 0 19·3% (14·6–24·7)
Latin America, tropical 22·0% (16·0–28·3) 44·2% (36·0–50·9) 2·8% (1·7–4·6) 2·7% (1·6–4·5) 1·7% (1·1–2·8) 0 26·6% (20·5–32·8)
North Africa/Middle East 25·1% (20·8–29·4) 41·4% (33·1–49·2) 1·8% (1·4–2·6) 1·4% (1·1–1·9) 1·6% (1·3–2·1) 3·7% (2·0–5·0) 25·0% (21·3–29·7)
North America, high income 21·1% (16·6–26·1) 47·8% (38·7–54·3) 4·5% (3·2–6·1) 2·4% (1·7–3·4) 2·4% (1·8–3·5) 0 21·9% (17·3–27·8)
Oceania 25·2% (20·1–31·5) 43·5% (35·4–50·6) 1·4% (0·99–2·1) 0·73% (0·51–1·1) 0·82% (0·56–1·3) 0 28·3% (22·7–33·9)
Sub-Saharan Africa, central 27·1% (22·2–32·4) 44·5% (35·5–51·3) 1·9% (1·3–2·9) 1·0% (0·71–1·5) 1·7% (1·2–2·5) 0·46% (0·20–0·85) 23·4% (19·6–28·6)
Sub-Saharan Africa, east 22·7% (19·3–26·6) 44·0% (35·4–50·6) 2·5% (1·9–3·2) 0·95% (0·76–1·2) 1·3% (1·0–1·7) 8·0% (6·5–9·6) 20·6% (17·3–24·6)
Sub-Saharan Africa, southern 24·2% (19·3–29·6) 45·9% (36·7–52·6) 2·8% (2·0–4·2) 1·5% (1·1–2·3) 1·7% (1·3–2·6) 0·85% (0·40–1·6) 22·9% (18·4–28·6)
Sub-Saharan Africa, west 24·3% (20·0–28·2) 43·8% (35·0–50·4) 1·4% (1·1–1·9) 0·93% (0·71–1·3) 1·6% (1·3–2·3) 4·3% (3·7–5·3) 23·7% (19·7–29·1)
Worldwide 25·6% (22·7–28·4) 51·1% (45·6–56·0) 1·9% (1·6–2·4) 1·2% (1·1–1·5) 1·3% (1·2–1·6) 1·3% (0·97–1·5) 17·6% (15·4–20·3)
2010
Asia Paciﬁ c, high income 15·2% (8·2–22·1) 48·1% (38·6–54·4) 6·0% (3·8–9·8) 3·7% (2·3–6·9) 3·1% (2·0–5·4) 0 23·9% (17·3–30·6)
Asia, central 18·7% (13·9–23·5) 46·5% (37·2–52·7) 5·0% (3·5–7·5) 3·6% (2·6–5·4) 2·8% (2·1–4·6) 0 23·4% (19·4–28·5)
Asia, east 13·4% (8·0–19·7) 46·1% (37·2–52·8) 5·2% (3·3–8·0) 1·6% (0·94–2·5) 0·84% (0·49–1·6) 1·2% (0·99–1·7) 31·6% (25·2–39·0)
Asia, south 21·4% (16·1–24·2) 65·4% (62·0–72·0) 1·0% (0·7–1·6) 1·6% (1·0–2·6) 2·1% (1·2–3·7) 0·08% (0·06–0·14) 8·6% (6·0–11·6)
Asia, southeast 22·7% (17·9–27·4) 44·2% (35·2–50·7) 1·8% (1·3–2·7) 1·8% (1·3–3·0) 1·2% (0·91–1·9) 0·10% (0·07–0·17) 28·1% (22·8–34·2)
Australasia 13·7% (8·4–20·8) 47·1% (37·7–53·5) 8·0% (5·1–12·6) 3·2% (1·9–5·9) 2·9% (1·8–5·9) 0 25·1% (17·4–32·4)
Caribbean 15·9% (11·4–21·3) 44·6% (36·3–51·2) 1·2% (0·90–1·9) 4·3% (3·1–6·4) 2·0% (1·5–3·2) 0·01% (0·00–0·02) 32·0% (25·7–38·4)
Europe, central 18·1% (13·2–23·4) 46·2% (36·7–52·7) 7·4% (5·2–11·0) 3·9% (2·8–6·0) 2·5% (1·8–4·0) 0 22·0% (17·5–27·0)
Europe, eastern 18·4% (11·8–26·2) 46·1% (37·1–52·6) 6·8% (4·0–10·9) 4·5% (2·6–7·7) 2·8% (1·8–5·2) 0 21·3% (14·4–29·1)
Europe, western 13·8% (10·3–18·3) 47·3% (38·5–53·7) 5·4% (4·1–7·5) 3·4% (2·5–4·9) 3·0% (2·4–4·5) 0 27·1% (22·5–32·9)
Latin America, Andean 14·8% (10·2–20·1) 44·6% (36·0–51·6) 3·1% (2·0–5·1) 4·5% (2·9–7·5) 2·2% (1·5–3·8) 0 30·8% (24·0–38·2)
Latin America, central 13·9% (9·9–18·8) 45·2% (36·2–51·6) 3·2% (2·2–5·0) 4·6% (3·2–7·1) 2·1% (1·6–3·5) 0 30·9% (24·7–37·3)
Latin America, southern 17·3% (10·7–23·2) 45·4% (36·5–52·0) 7·2% (4·5–11·5) 4·0% (2·5–6·3) 4·0% (2·6–6·8) 0 22·1% (15·9–28·7)
Latin America, tropical 13·9% (8·5–20·7) 45·4% (36·7–51·9) 6·0% (3·7–9·2) 5·2% (3·2–8·4) 2·2% (1·4–3·6) 0 27·3% (20·3–34·0)
North Africa/Middle East 18·0% (13·3–22·6) 43·2% (34·5–50·1) 4·1% (3·0–6·2) 3·0% (2·1–4·7) 2·4% (1·8–3·9) 2·1% (1·1–3·1) 27·1% (21·8–32·5)
North America, high income 13·0% (7·8–19·5) 48·1% (38·9–54·4) 5·5% (3·5–8·0) 3·4% (2·3–5·4) 2·8% (1·9–4·7) 0 27·3% (21·4–33·8)
Oceania 18·2% (12·1–25·4) 44·5% (35·8–51·3) 2·7% (1·7–4·8) 1·4% (0·85–2·5) 1·2% (0·77–2·3) 0 32·0% (24·2–40·1)
Sub-Saharan Africa, central 18·8% (12·8–24·3) 45·9% (36·8–52·4) 3·6% (2·1–6·2) 1·9% (1·2–3·3) 2·3% (1·6–4·0) 0·25% (0·10–0·53) 27·3% (21·4–35·4)
Sub-Saharan Africa, east 19·6% (15·8–23·6) 44·8% (36·0–51·0) 4·0% (3·0–5·5) 1·5% (1·1–2·2) 1·8% (1·4–2·6) 5·3% (4·2–6·9) 23·1% (19·0–28·0)
Sub-Saharan Africa, southern 17·8% (12·3–23·9) 46·7% (37·4–53·2) 4·8% (2·8–7·7) 2·6% (1·8–4·0) 2·5% (1·6–4·6) 0·47% (0·24–0·96) 25·2% (19·7–32·4)
Sub-Saharan Africa, west 15·6% (11·4–20·5) 44·8% (35·8–51·2) 2·9% (2·0–4·3) 1·8% (1·3–2·7) 2·7% (1·9–4·5) 2·5% (2·1–3·5) 29·6% (23·9–35·3)
Worldwide 18·4% (15·8–20·9) 52·9% (47·2–57·3) 3·1% (2·7–4·0) 2·2% (2·0–2·8) 1·9% (1·6–2·7) 0·71% (0·56–0·91) 20·8% (18·4–23·8)
Data are proportions (95% uncertainty intervals).
Table 3: Causes of moderate and severe vision impairment in 21 regions and worldwide in 1990 and 2010
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Figure 2: Prevalence of moderate and severe vision impairment in adults aged 50 years and older, by cause, in 21 regions and worldwide, from 1990 to 2010
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prevalence of blindness and vision impairment caused 
by trachoma-related corneal scarring, it contributed only 
5% to overall decline worldwide in blindness and 3% to 
overall decline worldwide in MSVI. Nevertheless, the 
reduction in corneal scarring from trachoma did make 
important contributions to decline in vision impairment 
in some regions, most notably in the east sub-Saharan 
Africa region, where it contributed 30% to decline in 
blindness and 21% to the decline in MSVI.
Discussion
We found that the major causes of blindness in 2010 
were, in order, cataract, uncorrected refractive error, and 
macular degeneration and for MSVI were uncorrected 
refractive error, cataract, and macular degeneration. 
Thus, despite the numbers of people aﬀ ected by blindness 
and MSVI due to cataract and trachoma decreasing and 
the number of people with uncorrected refractive error 
and age-related diseases, such as glaucoma, macular 
degeneration, and diabetic retinopathy, increasing, the 
leading causes were the same as in 1990. Causes of 
blindness diﬀ ered substantially by region, with the 
prevalence of cataract being lowest and that of macular 
degeneration being greatest in highest-income regions. 
Worldwide and in all regions, the proportion of blindness 
or MSVI caused by cataract and macular degeneration 
was higher in women than in men.
Avoidable vision loss due to preventable or treatable 
causes can be deﬁ ned as any vision loss due to cataract, 
uncorrected refractive error, trachoma, glaucoma, and 
diabetic retinopathy. With this deﬁ nition, of the 
31·8 million people blind in 1990, 68% (95% UI 65–70) 
had preventable or treatable causes. By 2010, the 
proportion had decreased to 65% (61–68) of 32·4 million 
blind, which was a signiﬁ cant change. Some of the 
blindness assigned to other causes, which comprised 
29% (26–31) of blindness in 2010, might also be 
preventable or treatable. For example, onchocerciasis is 
among the infectious preventable causes of blindness. 
Additionally, 76% (73–79) of MSVI in 2010 was preventable 
or treatable compared with 80% (78–83) in 1990.
Our ﬁ ndings are in agreement with those of previous 
studies that assessed the causes for vision loss within 
countries, regions, or worldwide. The combined data 
from studies done in Australia show that age-related 
macular degeneration was the major cause of severe 
vision impairment or blindness (deﬁ ned as visual acuity 
in the better eye of less than 2/200), aﬀ ecting 0·45% of 
the population.2 In a study in the Netherlands, myopic 
degeneration and optic neuropathy were the main causes 
of impaired vision among people younger than 75 years, 
whereas among people aged 75 years or older, age-related 
macular degeneration was the major cause of blindness.3 
In the Beijing Eye Study,18 the most frequent causes of 
blindness or MSVI were cataract, degenerative myopia, 
glaucoma, corneal opacity, and other optic-nerve damage. 
Age-related macular degeneration and diabetic 
retinopathy caused only a few cases. Studies in Latin 
America, central India, and east Asia also conﬁ rm the 
large proportion of presenting vision impairment due to 
uncorrected refractive errors (eg, 30% in Ecuador and 
72% in Brazil).19–22
This study is an extension of a series of meta-analysis 
investigations that started with a study by Thylefors and 
colleagues,5 which formed the basis for the 1999 launch 
of the Global Initiative for the Elimination of Avoidable 
Blindness, also known as VISION 2020: the Right to 
Sight.5 Since the publication of these worldwide data on 
blindness in 1995, population-based studies on the 
prevalence of blindness and vision impairment have 
been done in all WHO regions. Nevertheless, there 
remains a dearth of such information from regions such 
as central Africa, central and eastern Europe, and the 
Caribbean.11 Our study expands the data derived from a 
literature review published by WHO, which used the 
WHO program Prevention of Blindness and Deafness 
Programme for estimates.8 In that study, data from 2000 
to 2010 were assessed, and the analysis was limited to 
three age groups, with no breakdown by sex, and 
provided a point estimate for 2010 and estimates for the 
six WHO epidemiological world subregions.8 By contrast, 
we achieved a greater degree of granularity in our 
analysis by presenting data in 5-year age groups and by 
sex, we calculated time-series estimates for the period 
1990–2010, and make estimates for 21 regions. Thus, our 
estimates of prevalence of vision impairment have 
increased detail and show temporal changes.
The design of our study has potential limitations. First, 
as in our previous study on the global prevalence of vision 
loss,12 a major limitation was that data were unavailable or 
those that were available were at a subnational level for 
many country-years (appendix pp 3–18). Only a few 
national studies reported vision loss for all ages and all 
causes. Second, some data sources did not report 
prevalence by age (appendix pp 3–18). To use these data, 
we imputed age-speciﬁ c proportions for causes, based on 
the assumption that the age pattern of vision impairment 
in the study matched the modelled pattern in the country 
where the study was done.12 Third, the deﬁ nition of the 
diseases varied between studies. For instance, some 
studies deﬁ ned glaucoma according to the criteria of the 
International Society for Geographical and 
Epidemiological Society,23 whereas in others the 
appearance of the optic-nerve head was the main criterion, 
independent of the presence of visual-ﬁ eld defects. In 
terms of glaucoma, diﬀ erences in diagnostic criteria have 
led to a 12-fold diﬀ erence in reported prevalence.24 Fourth, 
the classiﬁ cation for macular degeneration included any 
macular disease and, therefore, we could not necessarily 
diﬀ erentiate between age-related macular degeneration, 
myopic maculopathy, and other retinal or macular 
disorders. Since myopic retinopathy is ranked among the 
three most common causes of vision impairment and 
blindness in some studies from east Asia, this mixed 
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grouping might prove important. The data from this 
analysis, therefore, cannot be used to reﬂ ect the role of 
myopic retinopathy, including myopic maculopathy, in 
vision impairment. Fifth, unidentiﬁ ed or other causes 
generally represented 20–30% of cause for MSVI and 
20–35% for blindness. Sixth, for 20 countries that are 
deemed by WHO to be endemic for trachoma, data on the 
prevalence of trachoma or trichiasis were not available. 
We had, therefore, to assume a conservative proportion of 
zero. This approach could have led to an underestimation 
of the prevalence of trachoma as cause for blindness and 
MSVI. Seventh, protocol dictates that population-based 
studies will report one principal cause per an individual 
assessed to arrive at the causal prevalence. When 
individuals had multiple disorders that could have 
contributed equally to visual loss, only the one deemed 
most readily curable or most easily preventable was 
recorded.25 This approach has the potential to 
underestimate the contribution of diabetic retinopathy, 
glaucoma, or other diseases with cataracts at presentation 
and to underestimate the burden of cataract when patients 
also have an uncorrected refractive error.26 Finally, some 
studies have small sample sizes, which leads to large 
conﬁ dence intervals for cause-speciﬁ c prevalence 
estimates. Our methods take into account sample size, 
which should lessen the eﬀ ect of small studies on the 
estimates compared with that of large studies.
The strengths of our study include the amount of 
population-based data accessed and used; analysis of 
trends in the causes of vision impairment; incorporation 
of non-linear age trends and the taking account of data 
that were not reported by age; and systematic quantitative 
analysis and reporting of uncertainty. The large network 
of ophthalmological researchers involved in identiﬁ cation 
and assessment of data sources ensured that we were 
able to access unpublished as well as published data: 
unpublished data were from 48 population-based studies, 
four government reports, and 44 rapid assessment of 
cataract surgical services and rapid assessment of 
avoidable blindness surveys. These data meant that 
studies for which investigators had published only 
summary data could be included. Thus, we assessed all 
major studies of vision impairment and included only 
those studies that met our inclusion criteria for 
representativeness of the population and clarity of visual 
acuity procedures and deﬁ nitions.
In conclusion, cataract or uncorrected refractive error 
led to 54% of blindness and 71% of MSVI in 2010. Both 
causes are easily and completely treatable. Glaucoma, 
macular degeneration, and trachoma were less frequent 
causes of vision loss. The proportions of vision 
impairment caused by cataract and trachoma decreased 
in the study period of 20 years; those for glaucoma, 
macular degeneration, and diabetic retinopathy 
increased; and that for uncorrected refractive error 
changed little. These temporal changes in cause-speciﬁ c 
prevalence of blindness and vision impairment are 
important for the setting of priorities, development of 
policies, and for planning (panel). Additionally, our data 
provide a resource for advocacy eﬀ orts to mobilise 
resources for eye-care services from governments, 
donors, and civil society.
Contributors
RRAB, GAS, JLS, and HP prepared the vision impairment survey data. 
GAS, RAW, JLS, and SRF analysed the data. RRAB, GAS, and JBJ wrote 
the ﬁ rst draft of the report. All authors contributed to the study design, 
analysis, and writing of the report. RRAB oversaw the research.
Conﬂ icts of interest
We declare that we have no conﬂ icts of interest.
Acknowledgments
This study was funded by the Bill & Melinda Gates Foundation, Fight for 
Sight, the Fred Hollows Foundation, and the Brien Holden Vision 
Institute. GAS is a staﬀ  member of WHO. The author alone is 
responsible for the views expressed in this publication and they do not 
necessarily represent the decisions, policy, or views of WHO. A list of 
members of the Vision Loss Expert Group appears at http://www.anglia.
ac.uk/ruskin/en/home/microsites/veru/other_research_areas/global_
burden_of_diseases.html. 
References
1 Sommer A, Tielsch JM, Katz J, et al. Racial diﬀ erences in the 
cause-speciﬁ c prevalence of blindness in east Baltimore. 
N Engl J Med 1991; 325: 1412–17.
2 Taylor HR, Keeﬀ e JE, Vu HTV, et al. Vision loss in Australia. 
Med J Aust 2005; 182: 565–68.
3 Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT. 
Age-speciﬁ c prevalence and causes of blindness and visual 
impairment in an older population: the Rotterdam Study. 
Arch Ophthalmol 1998; 116: 653–58.
4 Congdon N, O’Colmain B, Klaver CC, et al, for the Eye Diseases 
Prevalence Research Group. Causes and prevalence of visual 
impairment among adults in the United States. Arch Ophthalmol 
2004; 122: 477–85.
5 Thylefors B, Négrel AD, Pararajasegaram R, Dadzie KY. Global data 
on blindness. Bull World Health Organ 1995; 73: 115–21.
6 WHO. Global initiative for the elimination of avoidable blindness 
(WHO/PBL/97.61 Rev 2). Geneva: World Health Organization, 
2000.
7 Resnikoﬀ  S, Pascolini D, Etya’ale D, et al. Global data on visual 
impairment in the year 2002. Bull World Health Organ 2004; 
82: 844–51.
8 Pascolini D, Mariotti SP. Global estimates of visual impairment: 
2010. Br J Ophthalmol 2012; 96: 614–18.
9 Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life-years 
(DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: 
a systematic analysis for the Global Burden of Disease Study 2010. 
Lancet 2013; 380: 2197–223.
10 Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability 
(YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: 
a systematic analysis for the Global Burden of Disease Study 2010. 
Lancet 2013; 380: 2163–96.
11 Bourne R, Price H, Taylor H, et al, for the Global Burden of Disease 
Vision Loss Expert Group. New systematic review methodology for 
visual impairment and blindness for the 2010 Global Burden of 
Disease study. Ophthalmic Epidemiol 2013; 20: 33–39.
12 Stevens G, White R, Flaxman SR, et al. Global prevalence of visual 
impairment and blindness: magnitude and temporal trends, 
1990–2010. Ophthalmology 2013; published online July 10. 
DOI:10.1016/j.ophtha.2013.05.025.
13 Smith J, Mann R, Haddad D, et al. Global Atlas of Trachoma. http://
www.trachomaatlas.org (accessed Oct 17, 2013).
14 Peterson HM, Flaxman AD. Meta-regression with DisMod-MR: how 
robust is the model? Lancet 2013; 381: S110.
15 Myerson R, Rosenfeld LC, Lim SS, Murray CJL. Safe pregnancy and 
delivery: a systematic analysis of the trends in the coverage of 
antenatal and intrapartum care. In: Horton R, ed. Global health 
metrics and evaluation: controversies, innovation, accountability. 
Seattle, WA: Lancet, 2011: 85.
Articles
www.thelancet.com/lancetgh   Vol 1   December 2013 e349
16 WHO Global Health Observatory Data Repository. Trachoma: status 
of endemicity for blinding trachoma by country. http://apps.who.
int/gho/data/node.main.A1645?lang=en (accessed Oct 17, 2013). 
17 Ahmad O, Boschi-Pinto C, Lopez AD, et al. Age standardization of 
rates: a new WHO standard. Geneva: World Health Organization, 
2001.
18 Xu L, Wang Y, Li Y, et al. Causes of blindness and visual impairment 
in an urban and rural area in Beijing: the Beijing Eye Study. 
Ophthalmology 2006; 113: 1141.e1–e11.
19 Schellini SA, Durkin SR, Hoyama E, et al. Prevalence and causes of 
visual impairment in a Brazilian population: the Botucatu Eye 
Study. BMC Ophthalmol 2009; 9: 8.
20 Chang C, Cañizares R, Cuenca VJ, et al. Investigación rápida de la 
ceguera evitable. Estudio RAAB—Ecuador. Quito: RM Soluciones 
Graﬁ ca’s, 2009. 
21 Xu L, Li J, Cui T, Jonas JB. Frequency of under-corrected refractive 
error in elderly Chinese in Beijing. 
Graefes Arch Clin Exp Ophthalmol 2006; 244: 871–73.
22 Nangia V, Jonas JB, Sinha A, Gupta R, Bhojwani K. Prevalence of 
undercorrection of refractive error in rural Central India. The 
Central India Eye and Medical Study. Acta Ophthalmol 2012; 
90: E166–67.
23 Foster PJ, Buhrmann R, Quigley HA, et al. The deﬁ nition and 
classiﬁ cation of glaucoma in prevalence surveys. Br J Ophthalmol 
2002; 86: 238–42.
24 Wolfs RC, Borger PH, Ramrattan RS, et al. Changing views on 
open-angle glaucoma: deﬁ nitions and prevalences—The Rotterdam 
Study. Invest Ophthalmol Vis Sci 2000; 41: 3309–21.
25 WHO. Coding instructions for the WHO/PBL eye examination 
record (version III). http://www.who.int/ncd/vision2020_
actionplan/ documents/pbl_88_1.pdf (accessed Oct 17, 2013).
26 Kempen JH. The need for a revised approach to epidemiological 
monitoring of the prevalence of visual impairment. 
Ophthalmic Epidemiol 2011; 18: 99–102
